Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
NCT ID: NCT04667039
Last Updated: 2023-09-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
408 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-03-20
Study Completion Date
2024-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, double-blind, comparative, parallel group study of the efficacy, safety pharmacokinetics, and immunogenicity of GNR-067 and Lucentis® in patients with neovascular (wet) age-related macular degeneration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707
Macular Degeneration
COMPLETED
PHASE1/PHASE2
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
NCT00857259
Choroidal Neo-Vascular Age-onset Macular Degeneration
Age-related Macular Degeneration
TERMINATED
PHASE2
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
NCT02036723
Wet Age-related Macular Degeneration
WITHDRAWN
PHASE3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01940900
Age-Related Macular Degeneration
TERMINATED
PHASE3
Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
NCT01676506
Age-Related Macular Degeneration
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Age-related macular degeneration (ARMD) is a chronic progressive disease that is the main cause of visual disability in elderly patients (aged over 60 years) in industrialized countries. Due to increased human longevity, it is expected for the number of patients with this disease to grow worldwide up to 288 million people by 2040. The highest risk of vision loss is posed by neovascular (exudative or wet ARMD) macular degeneration observed in 10-20% of cases. The pathological changes of ARMD are based on the increased production of the vascular endothelial growth factor (VEGF) which affects proprioceptors located on the surface of endothelial cells and causes an anomalous permeability of vessels and stimulates neovascularization GNR-067 (JSC "GENERIUM", the Russian Federation) is a humanized recombinant monoclonal antibody selectively binding to the human vascular endothelial growth factor \[VEGF-A\] and is a biosimilar of of the original product Lucentis® ("Novartis Pharma AG", Switzerland).
This III phase study is aimed to compare the effectiveness, safety, pharmacokinetics and immunogenicity of GNR-067 (JSC "GENERIUM", the Russian Federation) and Lucentis® ("Novartis Pharma AG", Switzerland) in order to register of the drug GNR-067 (JSC "GENERIUM", the Russian Federation), a solution for intraocular injection administration, in the Russian Federation.
The study included patients (n = 408) aged 50 years and older with neovascular (wet) age-related macular degeneration, types 1 and 2 (occult and classical) choroidal neovascularization (CNV) with the following activity signs: accumulation of intraretinal and/or subretinal (under the neurosensory retina or pigment epithelium) fluid, extravasal dye exit from the newly formed vessels, and the presence of a subfoveal and/or juxtafoveal membrane and the presence of CNV foci of more than 50% of the total lesion area. With block randomization, the patients were divided into two groups in a 2:1 ratio (investigational/reference product): 272 patients to the group of the investigational product GNR-067 and 136 patients to the group of the reference product Lucentis®. The duration of the study for each patient will be approximately 52 ± 4 weeks, including a screening period (3 weeks), treatment period and a follow-up period (4 weeks). In this study GNR-067 and Lucentis® will be used intravitreally once every 4 weeks (thirteen injections in total) in 0.5 mg doses (the injection volume is 0.05 mL).
This III phase study is aimed to compare the effectiveness, safety, pharmacokinetics and immunogenicity of GNR-067 (JSC "GENERIUM", the Russian Federation) and Lucentis® ("Novartis Pharma AG", Switzerland) in order to register of the drug GNR-067 (JSC "GENERIUM", the Russian Federation), a solution for intraocular injection administration, in the Russian Federation.
The study included patients (n = 408) aged 50 years and older with neovascular (wet) age-related macular degeneration, types 1 and 2 (occult and classical) choroidal neovascularization (CNV) with the following activity signs: accumulation of intraretinal and/or subretinal (under the neurosensory retina or pigment epithelium) fluid, extravasal dye exit from the newly formed vessels, and the presence of a subfoveal and/or juxtafoveal membrane and the presence of CNV foci of more than 50% of the total lesion area. With block randomization, the patients were divided into two groups in a 2:1 ratio (investigational/reference product): 272 patients to the group of the investigational product GNR-067 and 136 patients to the group of the reference product Lucentis®. The duration of the study for each patient will be approximately 52 ± 4 weeks, including a screening period (3 weeks), treatment period and a follow-up period (4 weeks). In this study GNR-067 and Lucentis® will be used intravitreally once every 4 weeks (thirteen injections in total) in 0.5 mg doses (the injection volume is 0.05 mL).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Age Related Macular Degeneration (ARMD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Interventional
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Investigators
Throughout the study, until the end of the comparative treatment study period, neither the investigators nor the patients knew which drug was being administered
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GNR-067
Ranibizumab
Group Type
EXPERIMENTAL
Lucentis®
Intervention Type
BIOLOGICAL
Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
Lucentis®
Ranibizumab
Group Type
ACTIVE_COMPARATOR
GNR-067
Intervention Type
BIOLOGICAL
GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GNR-067
GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
Intervention Type
BIOLOGICAL
Lucentis®
Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Ranibizumab
Ranibizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Men and women aged 50 years and older;
2. The signed informed consent obtained from the patient, or, in cases of severe visual impairment in the patient, with the participation of an impartial witness, prior to any study-related procedures.
3. The previously diagnosed neovascular (wet) age-related macular degeneration confirmed at the Screening Visit:
untreated, except for food supplement, vitamins, mineral additives (one examined eye in one patient); Types 1 and 2 (occult and classical) choroidal neovascularization (CNV) with the following activity signs: accumulation of intraretinal and/or subretinal (under the neurosensory retina or pigment epithelium) fluid, extravasal dye exit from the newly formed vessels, and the presence of a subfoveal and/or juxtafoveal membrane and the presence of CNV foci of more than 50% of the total lesion area;
4. The best-corrected visual acuity within a range from 34 to 83 letters (20/200 to 20/25) measured using the ETDRS chart Early Treatment Diabetic Retinopathy Study Research Group protocol (chart at a distance of 4 m) before pupil dilation;
5. The willingness and ability of the patient to perform all planned study visits and procedures (according to the Investigator);
6. IOP ≤21 mmHg (actual);
7. An ECG within normal values or clinically insignificant findings.
2. The signed informed consent obtained from the patient, or, in cases of severe visual impairment in the patient, with the participation of an impartial witness, prior to any study-related procedures.
3. The previously diagnosed neovascular (wet) age-related macular degeneration confirmed at the Screening Visit:
untreated, except for food supplement, vitamins, mineral additives (one examined eye in one patient); Types 1 and 2 (occult and classical) choroidal neovascularization (CNV) with the following activity signs: accumulation of intraretinal and/or subretinal (under the neurosensory retina or pigment epithelium) fluid, extravasal dye exit from the newly formed vessels, and the presence of a subfoveal and/or juxtafoveal membrane and the presence of CNV foci of more than 50% of the total lesion area;
4. The best-corrected visual acuity within a range from 34 to 83 letters (20/200 to 20/25) measured using the ETDRS chart Early Treatment Diabetic Retinopathy Study Research Group protocol (chart at a distance of 4 m) before pupil dilation;
5. The willingness and ability of the patient to perform all planned study visits and procedures (according to the Investigator);
6. IOP ≤21 mmHg (actual);
7. An ECG within normal values or clinically insignificant findings.
Exclusion Criteria
1. Medical history of CNV treatment with intravitreal injections of VEGF inhibitors (ranibizumab, bevacizumab, aflibercept, or pegaptanib, etc.), or any other investigational poducts into the examined eye;
2. Medical history of subretinal laser photocoagulation or other surgical interventions for ARMD in any eye;
3. Preexisting and current lesions, diseases, or interventions in the eyes.:
In the examined eye:
Keratoplasty or corneal dystrophy Capsulotomy performed 4 weeks prior to screening Aphakia, vitrectomy Presence of a macular hole at any stage Past rhegmatogenous retinal detachment Any other past intraocular surgical interventions in the examined eye (including cataract extraction in the examined eye) within 3 months prior to the Screening Visit
In any eye:
Choroidal neovascularization in any eye due to reasons not related to ARMD (for example, multifocal choroiditis, ocular histoplasmosis syndrome, injury, etc.) Past idiopathic or autoimmune uveitis in any eye Scleromalacia Diagnosed diabetic retinopathy
Current conditions and diseases identified at the screening stage:
High degree myopia (over 8 diopters) in any eye; Presence of progressive glaucoma (intraocular pressure ≥21 mmHg against performed antihypertensive glaucoma therapy) or optic neuropathy that affect or endanger the central field of view in the examined eye at the screening stage; Subretinal hemorrhage and/or hemorrhage in the retinal tissue occupying ≥50% of the total affected area in the examined eye; Presence of a rupture (solution of continuity) of the retinal pigment epithelium (RPE) also extending to the macula in any eye; A scar or subretinal fibrosis in the macular area occupying more than 50% of the total affected area in any eye; Presence of vitreomacular traction or epiretinal membrane significantly affecting central vision; Other than ARMD progressive retinal diseases in the examined or fellow eye that may complicate the assessment of visual acuity; The total size of the lesion is more than 12 disc areas (DA: 30.5 mm2 including areas occupied by blood, neovascularization, or fibrosis), based on a FAG performed at screening; Confirmed or assumed (within 28 days prior to the Screening Visit) intraocular, extraocular, and periocular inflammation or infection in any eye.
4. Any intravitreal injections of corticosteroids (e.g., triamcinolone acetonide) for ≥30 days in a row in the examined eye 90 days prior to the Screening Visit and/or injection of an intravitreal corticosteroid implant with a gradual release of the medicinal product into the examined eye within 180 days prior to the Screening Visit;
5. Known allergic reactions and/or hypersensitivity to Lucentis® (ranibizumab) or any ingredients of GNR-067;
6. Known allergic reactions and/or hypersensitivity to fluorescein sodium (for injections);
7. Uncontrolled arterial hypertension (BP ≥180/90 mmHg);
8. Diseases of the immune and endocrine system, not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases);
9. Medical history or current (active cancer)of oncological diseases with the exception of cured basal cell carcinoma;
10. Vaccination (any vaccine) within 30 days prior to the Screening Visit and/or the need for vaccination during the study period;
11. Systemic treatment with corticosteroids (more than 10 mg of prednisolone equivalent) within 6 months prior to the Screening Visit;
12. Use of systemic medicinal products known to be toxic for the eye lens, retina, or optic nerve during the study.
13. Medical history of a clinically significant pathology identified during the screening period including, but not limited to:
Unstable angina pectoris, myocardial infarction, arrhythmia requiring drug therapy, Class III or IV congestive heart failure according to the New York Heart Association classification within one year before the Screening Visit; Brain injury, stroke, or transient ischemic attack within one year prior to the Screening Visit; Severe renal failure (estimated glomerular filtration rate according to the CKD-EPI formula \<40 mL/min/1.73 m2); Severe hepatic impairment (serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) activity of 2.5 or more times higher than the laboratory upper limit of normal (ULN), and/or the level of total bilirubin of 1.5 or more times higher than the laboratory ULN);
Variation of peripheral blood parameters:
Leukocytes: \<3.8 × 109/L Platelets: \<100 × 109 cells/L Hemoglobin: ≥10.0 g/dL
14. Pregnancy and breastfeeding;
15. Patients who received blood or blood component transfusions within 10 days prior to the Screening Visit;
16. History (within three years prior to the Screening Visit) of tuberculosis, alcoholism, narcotic, drug dependence and/or substance abuse, or presence of the above at the Screening stage;
17. Acute hepatitis or liver cirrhosis of any etiology; antibodies to hepatitis C or HBsAg at the Screening Visit; acquired immune deficiency syndrome or infection with human immunodeficiency virus (HIV) confirmed by test results;
18. Participation of the patient in any clinical studies and/or use of experimental medicinal products within 3 months prior to the Screening Visit.
2. Medical history of subretinal laser photocoagulation or other surgical interventions for ARMD in any eye;
3. Preexisting and current lesions, diseases, or interventions in the eyes.:
In the examined eye:
Keratoplasty or corneal dystrophy Capsulotomy performed 4 weeks prior to screening Aphakia, vitrectomy Presence of a macular hole at any stage Past rhegmatogenous retinal detachment Any other past intraocular surgical interventions in the examined eye (including cataract extraction in the examined eye) within 3 months prior to the Screening Visit
In any eye:
Choroidal neovascularization in any eye due to reasons not related to ARMD (for example, multifocal choroiditis, ocular histoplasmosis syndrome, injury, etc.) Past idiopathic or autoimmune uveitis in any eye Scleromalacia Diagnosed diabetic retinopathy
Current conditions and diseases identified at the screening stage:
High degree myopia (over 8 diopters) in any eye; Presence of progressive glaucoma (intraocular pressure ≥21 mmHg against performed antihypertensive glaucoma therapy) or optic neuropathy that affect or endanger the central field of view in the examined eye at the screening stage; Subretinal hemorrhage and/or hemorrhage in the retinal tissue occupying ≥50% of the total affected area in the examined eye; Presence of a rupture (solution of continuity) of the retinal pigment epithelium (RPE) also extending to the macula in any eye; A scar or subretinal fibrosis in the macular area occupying more than 50% of the total affected area in any eye; Presence of vitreomacular traction or epiretinal membrane significantly affecting central vision; Other than ARMD progressive retinal diseases in the examined or fellow eye that may complicate the assessment of visual acuity; The total size of the lesion is more than 12 disc areas (DA: 30.5 mm2 including areas occupied by blood, neovascularization, or fibrosis), based on a FAG performed at screening; Confirmed or assumed (within 28 days prior to the Screening Visit) intraocular, extraocular, and periocular inflammation or infection in any eye.
4. Any intravitreal injections of corticosteroids (e.g., triamcinolone acetonide) for ≥30 days in a row in the examined eye 90 days prior to the Screening Visit and/or injection of an intravitreal corticosteroid implant with a gradual release of the medicinal product into the examined eye within 180 days prior to the Screening Visit;
5. Known allergic reactions and/or hypersensitivity to Lucentis® (ranibizumab) or any ingredients of GNR-067;
6. Known allergic reactions and/or hypersensitivity to fluorescein sodium (for injections);
7. Uncontrolled arterial hypertension (BP ≥180/90 mmHg);
8. Diseases of the immune and endocrine system, not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases);
9. Medical history or current (active cancer)of oncological diseases with the exception of cured basal cell carcinoma;
10. Vaccination (any vaccine) within 30 days prior to the Screening Visit and/or the need for vaccination during the study period;
11. Systemic treatment with corticosteroids (more than 10 mg of prednisolone equivalent) within 6 months prior to the Screening Visit;
12. Use of systemic medicinal products known to be toxic for the eye lens, retina, or optic nerve during the study.
13. Medical history of a clinically significant pathology identified during the screening period including, but not limited to:
Unstable angina pectoris, myocardial infarction, arrhythmia requiring drug therapy, Class III or IV congestive heart failure according to the New York Heart Association classification within one year before the Screening Visit; Brain injury, stroke, or transient ischemic attack within one year prior to the Screening Visit; Severe renal failure (estimated glomerular filtration rate according to the CKD-EPI formula \<40 mL/min/1.73 m2); Severe hepatic impairment (serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) activity of 2.5 or more times higher than the laboratory upper limit of normal (ULN), and/or the level of total bilirubin of 1.5 or more times higher than the laboratory ULN);
Variation of peripheral blood parameters:
Leukocytes: \<3.8 × 109/L Platelets: \<100 × 109 cells/L Hemoglobin: ≥10.0 g/dL
14. Pregnancy and breastfeeding;
15. Patients who received blood or blood component transfusions within 10 days prior to the Screening Visit;
16. History (within three years prior to the Screening Visit) of tuberculosis, alcoholism, narcotic, drug dependence and/or substance abuse, or presence of the above at the Screening stage;
17. Acute hepatitis or liver cirrhosis of any etiology; antibodies to hepatitis C or HBsAg at the Screening Visit; acquired immune deficiency syndrome or infection with human immunodeficiency virus (HIV) confirmed by test results;
18. Participation of the patient in any clinical studies and/or use of experimental medicinal products within 3 months prior to the Screening Visit.
Minimum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AO GENERIUM
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oksana Markova, MD
Role: STUDY_CHAIR
AO GENERIUM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regional budgetary healthcare institution "Ivanovo Regional Clinical Hospital"
Ivanovo, Ivanovo Oblast, Russia
Site Status
NOT_YET_RECRUITING
State Budgetary Healthcare Facility of the St. Petersburg Region "First St. Petersburg State Medical University named after academician I.P. Pavlova "of the Ministry of Health of the Russian Federation
Saint Petersburg, Leningradskaya Oblast', Russia
Site Status
RECRUITING
Federal State Budgetary Educational Institution of Higher Education "Moscow State University of Medicine and Dentistry named after A.I. Evdokimov "of the Ministry of Health of the Russian Federation
Moscow, Moscow Oblast, Russia
Site Status
NOT_YET_RECRUITING
Federal State Autonomous Institution "Interbranch Scientific and Technical Complex" Eye Microsurgery "named after academician S.N. Fedorov "of the Ministry of Health of the Russian Federation
Moscow, Moscow Oblast, Russia
Site Status
NOT_YET_RECRUITING
State Budgetary Healthcare Institution of the Novosibirsk Region "State Novosibirsk Regional Clinical Hospital"
Novosibirsk, Novosibirsk Oblast, Russia
Site Status
RECRUITING
State Budgetary Healthcare Institution of the Omsk region "Clinical ophthalmological hospital named after V.P. Vykhodtseva"
Omsk, Omsk Oblast, Russia
Site Status
RECRUITING
State Autonomous Healthcare Institution "Republican Clinical Ophthalmological Hospital of the Ministry of Health of the Republic of Tatarstan" Kazan
Kazan', Tatarstan Republic, Russia
Site Status
NOT_YET_RECRUITING
Limited Liability Company "Kuzlyar"
Kazan', Tatarstan Republic, Russia
Site Status
NOT_YET_RECRUITING
Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
Kazan', Tatarstan Republic, Russia
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Russia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBS-AMD-III
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
NCT00967213
COMPLETED
PHASE3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01944839
TERMINATED
PHASE3
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
NCT00574093
COMPLETED
PHASE2
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
NCT02698566
COMPLETED
PHASE3
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
NCT00813891
UNKNOWN
PHASE4
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
NCT03805100
COMPLETED
PHASE3
Study EvAluating Genotypes While Using Lucentis 2
NCT01464723
COMPLETED
PHASE4
A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
NCT00567697
COMPLETED
PHASE3
Observation of Treatment Patterns With Lucentis in Approved Indications
NCT02194803
COMPLETED
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
NCT00517010
COMPLETED
EARLY_PHASE1
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
NCT05439629
COMPLETED
PHASE3
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
NCT00387582
COMPLETED
PHASE2
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
NCT04690556
COMPLETED
PHASE3
Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
NCT01123564
UNKNOWN
PHASE2
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
NCT01926977
COMPLETED
PHASE1/PHASE2
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT04740671
COMPLETED
PHASE3
Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
NCT00455871
UNKNOWN
NA
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
NCT04847895
COMPLETED
Photodynamic and Pharmacologic Treatment of CNV
NCT00570193
COMPLETED
PHASE1/PHASE2
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
NCT00429962
COMPLETED
PHASE3
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
NCT00413829
COMPLETED
PHASE2
Lucentis KAV Study
NCT01570608
COMPLETED
PHASE3
Lucentis in Advanced Macular Degeneration
NCT00896779
COMPLETED
PHASE2